LHC GROUP INC (LHCG) Stock Fundamental Analysis
NASDAQ:LHCG - Nasdaq - US50187A1079 - Common Stock - Currency: USD
Taking everything into account, LHCG scores 4 out of 10 in our fundamental rating. LHCG was compared to 103 industry peers in the Health Care Providers & Services industry. LHCG has an average financial health and profitability rating. While showing a medium growth rate, LHCG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LHCG was profitable.
In the past year LHCG has reported a negative cash flow from operations.
1.2 Ratios
The Return On Assets of LHCG (2.16%) is better than 66.09% of its industry peers.
LHCG has a Return On Equity of 3.94%. This is in the better half of the industry: LHCG outperforms 66.09% of its industry peers.
LHCG's Return On Invested Capital of 4.20% is fine compared to the rest of the industry. LHCG outperforms 62.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.16% | ||
| ROE | 3.94% | ||
| ROIC | 4.2% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LHCG's Profit Margin of 2.73% is fine compared to the rest of the industry. LHCG outperforms 65.22% of its industry peers.
LHCG's Profit Margin has improved in the last couple of years.
LHCG has a better Operating Margin (6.15%) than 68.70% of its industry peers.
In the last couple of years the Operating Margin of LHCG has grown nicely.
LHCG has a Gross Margin of 38.62%. This is in the better half of the industry: LHCG outperforms 68.70% of its industry peers.
In the last couple of years the Gross Margin of LHCG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.15% | ||
| PM (TTM) | 2.73% | ||
| GM | 38.62% |
OM growth 3Y2.47%
OM growth 5Y2.07%
PM growth 3Y14.06%
PM growth 5Y5.1%
GM growth 3Y3.28%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LHCG is destroying value.
Compared to 1 year ago, LHCG has less shares outstanding
Compared to 1 year ago, LHCG has a worse debt to assets ratio.
2.2 Solvency
LHCG has an Altman-Z score of 3.80. This indicates that LHCG is financially healthy and has little risk of bankruptcy at the moment.
LHCG has a better Altman-Z score (3.80) than 80.87% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that LHCG is not too dependend on debt financing.
LHCG has a Debt to Equity ratio of 0.46. This is in the better half of the industry: LHCG outperforms 64.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.8 |
ROIC/WACC0.5
WACC8.35%
2.3 Liquidity
A Current Ratio of 1.45 indicates that LHCG should not have too much problems paying its short term obligations.
LHCG has a Current ratio (1.45) which is in line with its industry peers.
A Quick Ratio of 1.45 indicates that LHCG should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.45, LHCG is in the better half of the industry, outperforming 61.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 |
3. Growth
3.1 Past
The earnings per share for LHCG have decreased strongly by -25.09% in the last year.
Measured over the past years, LHCG shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.42% on average per year.
Looking at the last year, LHCG shows a small growth in Revenue. The Revenue has grown by 6.44% in the last year.
The Revenue has been growing by 19.79% on average over the past years. This is quite good.
EPS 1Y (TTM)-25.09%
EPS 3Y18.36%
EPS 5Y22.42%
EPS Q2Q%-26.9%
Revenue 1Y (TTM)6.44%
Revenue growth 3Y7.04%
Revenue growth 5Y19.79%
Sales Q2Q%2.03%
3.2 Future
Based on estimates for the next years, LHCG will show a small growth in Earnings Per Share. The EPS will grow by 3.16% on average per year.
LHCG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.06% yearly.
EPS Next Y-22.68%
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
EPS Next 5Y3.16%
Revenue Next Year4.9%
Revenue Next 2Y5.12%
Revenue Next 3Y5.4%
Revenue Next 5Y7.06%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 38.68, which means the current valuation is very expensive for LHCG.
LHCG's Price/Earnings is on the same level as the industry average.
LHCG is valuated rather expensively when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
LHCG is valuated quite expensively with a Price/Forward Earnings ratio of 34.68.
Based on the Price/Forward Earnings ratio, LHCG is valued a bit cheaper than the industry average as 61.74% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.90. LHCG is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.68 | ||
| Fwd PE | 34.68 |
4.2 Price Multiples
LHCG's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 36.27 |
4.3 Compensation for Growth
LHCG's earnings are expected to decrease with -2.14% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)1.72
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
5. Dividend
5.1 Amount
LHCG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
169.81
+0.8 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.38%
Ins Owner Change0%
Market Cap5.27B
Analysts52.31
Price Target176.8 (4.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.89%
Min EPS beat(2)-28.55%
Max EPS beat(2)-21.23%
EPS beat(4)1
Avg EPS beat(4)-13.67%
Min EPS beat(4)-28.55%
Max EPS beat(4)1.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.18%
Min Revenue beat(2)-7.57%
Max Revenue beat(2)-6.79%
Revenue beat(4)0
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-7.57%
Max Revenue beat(4)-1.81%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.68 | ||
| Fwd PE | 34.68 | ||
| P/S | 2.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 36.27 |
EPS(TTM)4.39
EY2.59%
EPS(NY)4.9
Fwd EY2.88%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS74.37
BVpS51.57
TBVpS-17.57
PEG (NY)N/A
PEG (5Y)1.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.16% | ||
| ROE | 3.94% | ||
| ROCE | N/A | ||
| ROIC | 4.2% | ||
| ROICexc | 4.22% | ||
| ROICexgc | 24.13% | ||
| OM | 6.15% | ||
| PM (TTM) | 2.73% | ||
| GM | 38.62% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)7.29%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-4.92%
ROICexcg growth 5Y0.12%
ROICexc growth 3Y-3.77%
ROICexc growth 5Y-10.17%
OM growth 3Y2.47%
OM growth 5Y2.07%
PM growth 3Y14.06%
PM growth 5Y5.1%
GM growth 3Y3.28%
GM growth 5Y0.9%
F-Score3
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.46 | ||
| Cap/Depr | 100.43% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | 3.8 |
F-Score3
WACC8.35%
ROIC/WACC0.5
Cap/Depr(3y)217.37%
Cap/Depr(5y)282.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.09%
EPS 3Y18.36%
EPS 5Y22.42%
EPS Q2Q%-26.9%
EPS Next Y-22.68%
EPS Next 2Y-7.47%
EPS Next 3Y-2.14%
EPS Next 5Y3.16%
Revenue 1Y (TTM)6.44%
Revenue growth 3Y7.04%
Revenue growth 5Y19.79%
Sales Q2Q%2.03%
Revenue Next Year4.9%
Revenue Next 2Y5.12%
Revenue Next 3Y5.4%
Revenue Next 5Y7.06%
EBIT growth 1Y-34.33%
EBIT growth 3Y9.68%
EBIT growth 5Y22.27%
EBIT Next Year-13.1%
EBIT Next 3Y1.4%
EBIT Next 5Y2.66%
FCF growth 1Y-115.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.03%
OCF growth 3YN/A
OCF growth 5YN/A